FairJourney Biologics’ Post

Come learn more about how we support clients wanting to be sure they are providing world class services in their clinical trials that reduce burden and ensure equitable inclusion.

How CSLs Improved Feasibility Process Helps Study Teams Improve Their Robustness in Operational Planning Mireille Ermens, Senior Director, Clinical Development Operations—Global Feasibility and Start-Up Support, CSL Behring Mireille Ermens CSL Behring B.V. & Mary Smith Seqirus Early planning and study start-up challenges are common across the industry and may cause additional burden to study teams and sites with downstream impact on recruitment, timelines, and cost. Organisational focus is required to address these challenges. During this session you will learn how CSL has improved the feasibility process to help study teams improve their robustness in operational planning. https://bit.ly/3jRNCin #ScopeSummit #ClinicalTrials

Want to learn more about hot topics for pharmaceuticals regarding market access & public procurement? Join us at our upcoming PharmaAccess event in Paris! Register here: https://lnkd.in/ebcy8pSF hashtag #marketaccess hashtag #pharmaceuticals hashtag #publicprocurement

Happy World Thrombosis Day! Definitely thank you to sponsors of Workd Thrombosis Day and #Thrombosis Uk The main take home message is THINK VTE!!! Why is my leg aching ???DVT I don’t understand why I’m short of breath- was okay last week. ???? Pulmonary embolism One of main reasons for death due to clots in lungs is 1. lack of awareness of symptoms (so we don’t go to GP) 2. Lack of knowledge of VTE by healthcare professionals- (delay in diagnosis ) We can reduce the deaths by just asking the question- could this be a clot?? The signs are symptoms do NOT always follow the textbook definitions, but there is often a hint:- 1. Recently stopped taking blood thinners, 2. Recently had a big operation, 3. Recently had a baby THINK VTE have a great Sunday.

💥 Unveiling the REAL expectations from Service Providers in the Clinical Trial Industry! 💼 Dive into the insights shared by our dynamic panelists at the 20th BioPharma Clinical Trials Nexus in San Diego! 🔍 #ClinicalTrials #IndustryInsights #FlippingTheDialogue 💪

I am ecstatic to share that I have secured a substantial grant of approximately $850,000 on behalf of Genentech Oceanside Technical Operations from the California Employment Training Panel (ETP) to enhance workforce skills. This grant will facilitate upskilling and reskilling training for the dedicated employees at Genentech Oceanside, focusing on both the legacy stainless steel and the new Oceanside Single Use Technology (OSUT) biologics manufacturing facilities. The training, reimbursable under a single employer contract with critical proposal enhancement via GO-Biz, targets manufacturing staff across both facilities, including personnel from Manufacturing Science and Technology, Quality Assurance, Quality Control, and other essential site functions. The initiative underscores the critical need for a well-trained workforce in Southern California's biopharma sector, offering competitive wages and ensuring Genentech's sustainability in next-generation bio manufacturing. The investment in workforce development, complemented by ongoing corporate training initiatives, aligns with Genentech's commitment to innovation and sustainability. The new OSUT facility promises expedited medicine delivery to patients, reduced resource consumption, and zero plastic waste to landfills. A proficient workforce is essential for the success of this advanced facility, emphasizing the significance of ETP's support for the proposal. Special appreciation goes to key individuals at Genentech, including Joaquín Castañeda, Sierra Shebest and Rita A. and the collaborative efforts of Rebecca Eusey and teams at ETP and the Governor's Office of Business and Economic Development. 👏👏

First 5 years of Knight in Latin America

🎉 Proud Moment Alert! 🎉 Today, we celebrate the 175th Anniversary of Pfizer, a legacy of breakthroughs, innovation, and unwavering commitment to healthcare. Reflecting on my journey since joining this incredible team in 2015, I'm overwhelmed with gratitude. Pfizer's story is a global movement towards a healthier world, not just about a company. Throughout its rich history, Pfizer has led medical innovation, from pioneering the first mass-produced antibiotic to combating global health crises. As we step into this significant year, the collaborative spirit, resilience, and dedication that define Pfizer are evident. It's a privilege to be part of a community making history every day. To all colleagues, past and present, your contributions have shaped Pfizer into what it is today. Together, we've witnessed and made history. Here's to celebrating 175 years of innovation, diligence, and compassion. Looking to the future, I anticipate the new chapters we are yet to write. May we lead with purpose, drive forward our mission, and touch more lives with our work. #Pfizer175 #Innovation #Healthcare #AnniversaryCelebration #MakingHistory #PfizerProud

AstraZeneca announces another strong set of results for Q2 and upgrades the full year revenue and EPS guidance. Oncology remains a strong pillar driving sales growth in high double digits. A move into oral agents for obesity looks interesting with an oral GLP-1 agent and two others with novel modes of action that are likely to be positioned for obesity patients with co-morbidities such as hypertension and Chronic Kidney Disease. By 2030, AstraZeneca aims to double revenue to $80 billion. And unlike others that make claims, AZ says "how" it will realise these aspirations. Today, based on a global revenue of $40 billion, the AZ share price is £120. I can't wait to see the share price with a revenue of $80 billion! Sadly, this Labour Government will rob me with Capital Gains Tax, which they will surely raise in this Autumn's budget (double the tax rate to 20% and 40% for higher rate taxpayers). Robbing bar stewards!

https://lnkd.in/eaGFdW3S Johnson & Johnson (NYSE:JNJ) today announced new frontline data featuring TECVAYLI® (teclistamab-cqyv) from two investigational studies in patients with newly ...